GSK (GSK) announced that its adjuvanted recombinant respiratory syncytial virus, RSV, vaccine, Arexvy, has been approved by the European Commission, EC, for use in adults aged 18 years and older. Arexvy was the first RSV vaccine authorised in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV. It was previously approved in adults aged 60 years and above, as well as in those aged 50 to 59 years who are at increased risk for RSV disease. Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases Research and Development, said: “This approval helps protect all adults aged 18 and older in Europe against RSV, a potentially serious respiratory infection that can lead to significant illness, hospitalisation and even death, particularly for those with certain underlying health conditions. GSK is proud to expand prevention options against RSV across Europe.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Drugmakers use AI to help progress through trials, submissions, Reuters says
- GSK announces China’s NMPA approved new indication for Trelegy Ellipta
- GSK Halts Early-Stage Sickle Cell Study, Tweaking the Risk Profile of Its Rare Disease Pipeline
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?
- GSK and Alector Phase 3 Dementia Trial Ends Early: What Investors Need to Know